Table 2.

PK Parameters by Treatment Group

Variable	Tiotropium solution									Tiotropium powder
	1.25 µg			2.5 µg			5.0 µg			18.0 µg
	n	gMean	gCV (%)	n	gMean	gCV (%)	n	gMean	gCV (%)	n	gMean	gCV (%)
Cmax,ss (pg/mL)	104	2.8	53.0	110	5.1	61.8	113	10.5	66.4	113	12.9	64.6
Cmax,ss,norm (pg/mL/µg)	104	2.3	53.0	110	2.0	61.8	113	2.1	66.4	113	0.7	64.6
AUC0–6h,ss (pg · h/mL)	22	10.0	25.3	76	12.8	29.9	107	22.1	47.8	113	28.4	52.4
AUC0–6h,ss,norm (pg · h/mL/µg)	22	8.0	25.3	76	5.1	29.9	107	4.4	47.8	113	1.6	52.4
AUC0–1h,ss (pg · h/mL)	61	2.1	32.3	97	3.2	44.4	112	6.1	58.3	113	7.8	54.9
AUC0–1h,ss,norm (pg · h/mL/µg)	61	1.7	32.3	97	1.3	44.4	112	1.2	58.3	113	0.4	54.9
Ae0–6h,ss (ng)	108	88.7	68.0	110	177	68.0	107	387	65.9	109	522	53.8
f0–6h,ss (%)	108	7.09	68.0	110	7.1	68.0	107	7.8	65.9	109	2.9	53.8
tmax,ss (h)a	104	0.100	0.0330–2.00	110	0.0830	0.0330–6.00	113	0.117	0.0330–0.333	113	0.117	0.0330–1.00

Ae_0–6h,ss, amount of drug excreted in urine from 0 to 6 hours at steady state; AUC_0–1h,ss, area under the plasma concentration–time profile from 0 to 1 hour at steady state; AUC_{0–1h,ss,norm}, normalized area under the plasma concentration–time profile from 0 to 6 hours at steady state; AUC_0–6h,ss, area under the plasma concentration–time profile from 0 to 6 hours at steady state; AUC_{0–6h,ss,norm}, normalized area under the plasma concentration–time profile from 0 to 6 hours at steady state; C_max,ss, peak plasma concentration at steady state; C_max,ss,norm, normalized peak plasma concentration at steady state; f_0–6h,ss, fraction of the delivered dose excreted in urine from 0 to 6 hours at steady state; gCV, geometric coefficient of variation; gMean, geometric mean; t_max,ss, time to C_max at steady state.

^aMedian and range.